Alzheimers Therapeutic Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

This report on global Alzheimer's therapeutics market studies various drugs used for the treatment of Alzheimer's along with pipeline analysis of upcoming potential drugs. According to the Institute of Health Metrics and Evaluation, Alzheimer's is one of the most common diseases that cause dementia, which leads to a loss of cognitive abilities, including reasoning, thinking, and remembering. Alzheimer's is an irreversible, progressive brain disease that eventually destroys the ability to carry out the most basic tasks of daily living. While treatments to manage symptoms are available, Alzheimer's has no cure. Thus, the drug pipeline of Alzheimer's treatment market comprises potential drugs which are more target specific and posses innovative properties.

For the purpose of this study, the various drugs studied include memantine hydrochloride donepezil hydrochloride rivastigmine and galantamine hydrobromide. The pipeline analysis for Alzheimer's therapeutics market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials. The geographic segmentation of the global Alzheimer's therapeutics market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries.

According to Alzheimer's Society, there are no drug treatments that can cure Alzheimer's disease or any other common type of dementia. However, medicines have been developed for Alzheimer's disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer's disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist.

According to press release published by BioArctic Neuroscience AB, the Alzheimer's disease is age-related and the number of patients doubles every five years beyond age 65, meaning that 30% of 85-year-olds are suffering from the disease. Current estimates indicate 35.6 million people worldwide are affected and researchers estimate that this number could triple by 2050. According to medical practitioners, donepezil, rivastigmine or galantamine is offered as part of treatment for patients with mild-to-moderate Alzheimer's disease. However, use of memantine is for severe Alzheimer's disease and most of the medical practitioners recommend memantine for people with moderate Alzheimer's disease who cannot take the cholinesterase inhibitor drugs. The current market dynamics suggest that drugs currently available in the market are expected to lose their exclusivity during the forecast period. Hence, the current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies

According to Alzheimer's Association, if no novel treatments are found to prevent, delay or stop the progression of Alzheimer's disease, the number of people affected in the U.S. is expected to soar to 15 million by 2050 and the cost of care for Alzheimer's patients could increase five-fold to $1.2 trillion a year. The drugs currently available in Alzheimer's therapeutics market treat the cognitive symptoms of the disease such as memory loss, confusion and problems with thinking but do not address the underlying causes of the disease. However, ongoing research on Alzheimer's treatment is focused on treatments that may restrain or slow down disease progression disease modifying agents. Other areas of research are concentrating at the role inflammation and insulin resistance developed in Alzheimer's disease. According to market experts the major challenges in Alzheimer's clinical trials are as follows:

• Recruitment and retention of clinical trial participants
• Acquiring the essential augmented funding for clinical trials (federal and private both)
• Collecting informed consent from patients who are suffering from the effects of the disease
• Involving caregivers in research trials because they can actually add an extra burden to their daily routine

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alzheimer's Therapeutic market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Alzheimer's Therapeutic market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

• Memantine Hydrochloride
• Donepezil Hydrochloride
• Rivastigmine
• Galantamine Hydrobromide
• Pipeline Analysis
• Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
• ENA713
• Flutemetamol (18F)
• LY450139
• Dimebon
• Aripiprazole/ BMS-337039
• Tabular Representation of Phase II and I Drugs

Key Questions Answered in this Report

• What are the key micro and macro environmental factors that are impacting the growth of Alzheimer's Therapeutic market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Alzheimer's Therapeutic market?
• Which is the largest regional market for Alzheimer's Therapeutic market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Alzheimer's Therapeutic market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Alzheimer's Therapeutic market worldwide?

This product will be delivered within 2 business days.